High materiality8/10
Lyell Immunopharma (LYEL) Reiterated at Market Outperform by Citizens
Why it may matterVerify against the original reporting
Upside potential confirmed by upward target.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
RBC Capital reiterates Market Outperform on LYEL with a target of $34. Current price is $13.74. Price Change Since Signal: +$1.53.
- Target: $34
- Posted price: $13.74
- Analyst firm: RBC Capital
Key facts
- 01
Target: $34
- 02
Posted price: $13.74
- 03
Analyst firm: RBC Capital
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.